Cercar
16/02/2022
Effect of statin therapy on SARS-CoV-2 infection-related mortality in hospitalized patients
Masana, L, Correig, E, Rodriguez-Borjabad, C, Anoro, E, Arroyo, JA, Jerico, C, Pedragosa, A, la Miret, M, Naf, S, Pardo, A, Perea, V, Perez-Bernalte, R, Plana, N, Ramirez-Montesinos, R, Royuela, M, Soler, C, Urquizu-Padilla, M, Zamora, A, Pedro-Botet, J. Effect of statin therapy on SARS-CoV-2 infection-related mortality in hospitalized patients. European Heart Journal-Cardiovascular Pharmacotherapy. 2022; 8(2)DOI:10.1093/ehjcvp/pvaa128. PMID:33135047. IF:7.100(Q1/1D).
01/01/2022
Experts document on methotrexate use in combined therapy with biological or targeted synthetic disease modifying drugs in patients with rheumatoid arthritis
Tornero-Molina, J, Alperi-Lopez, M, Castellvi, I, de Agustin-de Oro, JJ, Escudero, A, Garcia-Vicuna, R, Gonzalez-Gay, MA, Hidalgo, C, Rubio, E, Sanmarti, R, Casamira, N, Calvo-Alen, J. Experts document on methotrexate use in combined therapy with biological or targeted synthetic disease modifying drugs in patients with rheumatoid arthritis. Reumatologia Clinica. 2022; 18(1)DOI:10.1016/j.reuma.2020.08.003. PMID:35090610. IF:(Q/D).
01/01/2024
Altered CD39 and CD73 Expression in Rheumatoid Arthritis: Implications for Disease Activity and Treatment Response
Ortiz, MA, Diaz-Torne, C, De Agustin, JJ, Estrada, P, Reina, D, Hernandez, MV, Sang, HY, Zamora, C, Canto, E, Corominas, H, Vidal, S. Altered CD39 and CD73 Expression in Rheumatoid Arthritis: Implications for Disease Activity and Treatment Response. Biomolecules. 2024; 14(1)DOI:10.3390/biom14010001. PMID:38275742. IF:4.800(Q1/3D).
01/01/2024
Initial Treatment with Biological Therapy in Rheumatoid Arthritis
Molina, JT, Hernández-Cruz, B, Corominas, H. Initial Treatment with Biological Therapy in Rheumatoid Arthritis. Journal of Clinical Medicine. 2024; 13(1)DOI:10.3390/jcm13010048. PMID:38202055. IF:2.900(Q1/2D).
01/12/2023
Recommendations by the Spanish Society of Rheumatology on risk management of biological treatment and JAK inhibitors in patients with rheumatoid arthritis
Balsa A., Díaz del Campo Fontecha P., Silva Fernández L., Valencia Martín J., Nistal Martínez V., León Vázquez F., Hernández Hernández M.V., Corominas H., Cáliz Cáliz R., Aguado García J.M., Candelas Rodríguez G., Ibargoyen Roteta N., Martí Carbajal A., Plana Farras M.N., Puñal Riobóo J., Park H.S., Triñanes Pego Y., Villaverde García V.. Recommendations by the Spanish Society of Rheumatology on risk management of biological treatment and JAK inhibitors in patients with rheumatoid arthritis. Reumatologia Clinica. 2023; 19(10)DOI:10.1016/j.reuma.2023.07.001. PMID:. IF:(Q/D).
24/11/2023
Impact of IL6R genetic variants on treatment efficacy and toxicity response to sarilumab in rheumatoid arthritis
Sainz, L, Riera, P, Moya, P, Bernal, S, Casademont, J, Diaz-Torne, C, Millan, AM, Park, HS, Lasa, A, Corominas, H. Impact of IL6R genetic variants on treatment efficacy and toxicity response to sarilumab in rheumatoid arthritis. ARTHRITIS RESEARCH & THERAPY. 2023; 25(1)DOI:10.1186/s13075-023-03209-1. PMID:38001504. IF:4.400(Q1/3D).
23/10/2023
Dual targeted therapy in patients with psoriatic arthritis and spondyloarthritis: a real-world multicenter experience from Spain
Valero-Martínez, C, Urgelles, JF, Sallés, M, Joven-Ibáñez, BE, de Juanes, A, Ramírez, J, Juanola, X, Almodóvar, R, Laiz, A, Moreno, M, Pujol, M, Beltrán, E, Pinto-Tasende, JA, Crespí, L, Sala-Icardo, L, Castañeda, S, García-Vicuña, R. Dual targeted therapy in patients with psoriatic arthritis and spondyloarthritis: a real-world multicenter experience from Spain. Frontiers in Immunology. 2023; 14DOI:10.3389/fimmu.2023.1283251. PMID:37936691. IF:5.700(Q1/3D).
01/07/2023
Impaired Regulation by IL-35 in Systemic Sclerosis
Osuna-Gomez, R, Castellvi, I, Mulet, M, Ortiz, MA, Brough, DE, Sabzevari, H, Semnani, RT, Vidal, S. Impaired Regulation by IL-35 in Systemic Sclerosis. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2023; 24(13)DOI:10.3390/ijms241310567. PMID:37445745. IF:4.900(Q1/3D).